BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7629253)

  • 1. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
    Scillitani A; Dicembrino F; Di Fazio P; Vettori PP; D'Angelo V; Scarabino T; Liuzzi A
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
    Pirker W; Brücke T; Riedl M; Clodi M; Luger A; Asenbaum S; Podreka I; Deecke L
    J Neural Transm Gen Sect; 1994; 97(3):235-44. PubMed ID: 7873131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N; Rambaldi PF; Battista C; Ambrosio G; Cascini GL; Schillirò F; Mansi L
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.
    Verhoeff NP; Bemelman FJ; Wiersinga WM; van Royen EA
    Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic imaging of dopamine receptors in pituitary adenomas.
    de Herder WW; Reijs AEM; Feelders RA; van Aken MO; Krenning EP; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S53-S56. PubMed ID: 17413189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels.
    Smith MV; Laws ER
    Neurosurgery; 1994 May; 34(5):834-9; discussion 839. PubMed ID: 8052379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.
    Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW
    J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disappearance of the radiographic image of a macroprolactinoma after treatment with bromocriptine].
    Forsbach G; Olivares F; Vázquez J; Güitrón A
    Ginecol Obstet Mex; 1998 Apr; 66():170-2. PubMed ID: 9617019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
    Kung HF; Alavi A; Chang W; Kung MP; Keyes JW; Velchik MG; Billings J; Pan S; Noto R; Rausch
    J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.